Corporate Profile for Boehringer Mannheim Corp., dated Sept. 20, 1996.
These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0-
Published Date: Sept. 20, 1996
Company Name: Boehringer Mannheim Corp., Therapeutics Division
Address: 101 Orchard Ridge Drive Gaithersburg, MD 20878
Main Telephone Number: 800/628-2672
Senior VP U.S. Therapeutics: John Melville
Manager, Marketing Communications Contact: Kevin Kramer Business number: 301/216-3733 e-mail address: email@example.com
Industry: Pharmaceutical, Biotechnology-0-
Company description: Boehringer Mannheim Corp., Therapeutics Division (BMCT) was established in 1984 in Rockville, Md. BMCT is a division of Boehringer Mannheim Corp. (BMC) located in Indianapolis. With divisions in Diagnostics, Therapeutics, and Biochemicals, BMC is the U.S. member of the Boehringer Mannheim Group of Mannheim, Germany. Boehringer Mannheim has operating divisions in 26 countries, and products available in 150 countries.
After building a drug development group, BMCT sales and marketing launched its first commercial product, ISMO for chronic stable angina, followed in 1994 by DEMADEX, a loop diuretic for the treatment of edema associated with congestive heart failure. Along with DEMADEX and ISMO, BMCT currently markets CARDIAC T Rapid Assay and MICRAL in partnership with BMC Diagnostics.
BMCT moved to Gaithersburg in 1994 and currently employs over 400 in the United States, including a field sales force of 265 representatives. BMCT focuses on research, development and marketing of products in the following therapeutic areas: cardiovascular, renal, oncology, metabolism (bone and diabetes), antivirals/antiinfectives, and gene medicine. The parent company of BMCT was one of the first to develop synthetic pharmaceuticals, formulate early intravenous drugs for cardiac patients, introduce oral anti-diabetic agents, and pioneer biotechnology drug development.
Boehringer Mannheim has built a heritage of quality worldwide with over 140 years of experience. Today, Boehringer Mannheim's principal biotechnology facility in Penzburg, Germany is fully equipped to handle all levels of biotechnological development with more than 1,500 biotechnology products and approximately 200 recombinant products.
Industry: Biotechnology Segment: Human Therapeutics Ownership: Subsidiary Employees: 400 Revenue: (US $ mil.) Sales: 3.27 billion - 1995
CONTACT: Boehringer Mannheim
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 20, 1996|
|Previous Article:||Corporate Profile for Institutional Shareholder Services, dated Sept. 20, 1996.|
|Next Article:||Corporate Profile for InterDigital, dated Sept. 20, 1996.|